Alex Gorsky on patient outcomes
From Recursion's "Era of TechBio" Panel at JPM Featuring Dean Li, Kimberly Powell, Alex Gorsky & Tony Kim · · Recursion
“I think as we consider both those questions that we uh we need to remember two of the fundamental drivers why all of us are here and why we do what we do and one is ultimately what is it going to do to help patients right and um and it can be easy to be get caught up into science experiments it can easy be easy to get caught up into um you applications that ultimately may not be differentiated uh or in in in reality more effective or safer than what's currently available and keeping that in mind and number two the question about value and what value are we actually providing what value are we creating because ultimately if we don't do that the machine can't keep going uh and um so I think just keeping those two things in mind as we consider those questions and the application of this technology going mov forward in in our really special industry”
On , Alex Gorsky, Former Executive Chairman & Chief Executive Officer at Johnson & Johnson, spoke about patient outcomes during Recursion's "Era of TechBio" Panel at JPM Featuring Dean Li, Kimberly Powell, Alex Gorsky & Tony Kim on Recursion.
About Alex Gorsky
Alex Gorsky, former Executive Chairman and CEO of Johnson & Johnson, participated in a keynote discussion at the LSI USA '24 Emerging Medtech Summit in May 2024. During the conversation, he argued that the traditional model of pricing medical devices with a small performance difference at a significantly higher cost "is not going to work." He stated that healthcare spending will increase over the next decade due to demographic shifts, and he described this as "not a bad thing" for a developed society. Gorsky also warned that if the industry does not focus on ensuring broad access to technology, "countervailing political forces" could change the healthcare ecosystem. He noted that large-scale M&A is "quite challenged" and expressed concern about that trend. Gorsky predicted that enabling technologies like cloud, connectivity, and AI will become the focus of medtech within ten years, and he advised entrepreneurs and investors to "think differently" about enabling the next generation of healthcare. Earlier, during the COVID-19 pandemic in 2020, Gorsky discussed Johnson & Johnson's development of a vaccine on a not-for-profit basis, stating that the company aimed to provide broad access. He emphasized the importance of relying on "data, science, and well-established regulatory guidelines" during a politicized time. In a 2018 interview, Gorsky described leading Johnson & Johnson with a "start-up mode" mindset, stressing the need for constant reinvention. He also discussed the importance of the company's Credo, a set of principles he said serves as a "moral compass," and noted that all employees had participated in "Credo challenge" sessions to discuss its relevance. In a 2013 interview, Gorsky identified significant organizational and people changes as among the most challenging decisions he faced, and he said he evaluates leaders based on their performance, their track record in developing future leaders, and how they develop talent with the Credo in mind.